Pure Global AI
NCT06078995Recruiting

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China a Real-world, Multicenter, Retrospective, Controlled Study
Huashan HospitalClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ischemic Stroke
Drug/Device/Intervention
Tenecteplase
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Huashan Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Apr 02, 2023
End date
May 01, 2024
Enrollment
1200 participants
Primary outcome

Rate of patients with symptomatic intracranial hemorrhage within 36 hours

Summary

The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in
 acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical
 setting.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedOther cerebral infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06078995
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06078995 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 1200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.